Sensorion Company Description

Sensorion SA, a biotechnology company, develops drug candidates for the treatment of inner ear disorders in France.

Its pipeline includes various products in the development stage for restoring, treating, and preventing inner ear related disorders.

The company’s product portfolio includes SENS-401 SSNHL, which has completed Phase 2 clinical trial for the treatment of Sudden Sensorineural Hearing Loss; SENS-401 CIO that is in Phase 2 clinical trial for the treatment of Cisplatin-Induced Ototoxicity; and SENS-401 Cochlear, which is in Phase 2 clinical trial for the treatment of hearing preservation after cochlear implantation.

It is also developing OTOF-GT (SENS-501), a gene therapy development program that has completed Phase 1 clinical trial to restore hearing in people living with Otoferlin deficiency; and GJB2-GT, a gene therapy development program, which is in pre-clinical trial to restore hearing in people living with hearing loss due to mutations in the GJB2 gene.

The company was incorporated in 2009 and is headquartered in Montpellier, France.

Sensorion SA

Country	France
Founded	2009
Industry	Biotechnology
Sector	Healthcare
Employees	57
CEO	Nawal Ouzren

Contact Details

Address: 375, rue du Professeur Joseph Blayac Montpellier, 34080 France
Phone	33 4 67 20 77 30
Website	sensorion.com

Stock Details

Ticker Symbol	ALSEN
Exchange	Euronext Paris
Fiscal Year	January - December
Reporting Currency	EUR
ISIN Number	FR0012596468
SIC Code	2834

Key Executives

Name	Position
Nawal Ouzren	Chief Executive Officer and Director
Laurene Danon	Chief Financial Officer
Bernd Schmidt	Chief Technical Officer
Dr. Geraldine Honnet M.D.	Chief Medical Officer
Christine Le Bec	Head of CMC Gene Therapy
Stephanie Filipe	Head of the Project Management Office
Laurent Desire	Head of Preclinical Development
Rachel Cooper	Head of Audiology